Supernus Pharmaceuticals (SUPN) PT Lowered to $62 at BofA Securities

April 27, 2026 5:21 AM

BofA Securities analyst Pavan Patel lowered the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $62.00 (from $65.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found